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Background: Superficial infections of the skin and mucous membranes caused by dermatophyte fungi are
amongst the most common and challenging infections to treat. Previously we demonstrated the phototoxic effects
of photodynamic therapy (PDT) towards Trichophyton rubrum, using a green laser to photoactivate Rose Bengal
(RB). The aim of this study was to evaluate whether we could; (1) achieve a similar effect using an inexpensive
light-emitting diode (LED) to photoactivate RB and (2) to evaluate whether our PDT regime could be combined
with standard antifungal drug therapy and increase its effectiveness.
Methods: We designed and built our own inexpensive green (530 nm) LED source and tested its efficacy as part
our RB-PDT regime in vitro against T. rubrum. We also examined the potential benefits of incorporating PDT as part
of combination therapy and whether the order in which this was done had an impact. First we subjected spore
suspensions to sub-inhibitory concentrations of a number of antifungal agents (CLT, MCZ and TRB) for 72 hours
followed by RB-PDT. Secondly we subjected spore suspensions to sub-inhibitory PDT followed by drug treatment
and evaluated if there were any changes to the minimum inhibitory concentrations (MICs) of the drugs tested.
Results: The optimal conditions for photoinactivation of T. rubrum using RB-PDT alone were 140 μM of RB and
24 J/cm2 of LED (equating to a 30-minute exposure). These parameters also caused a 100% reduction in the viability
of the pathogenic yeast Candida albicans and the model fungus Saccharomyces cerevisiae. By combining our RB-PDT
regime as an adjunct to antifungal drugs we were able to dramatically reduce the exposure times. Treatment of spore
suspensions using a sub-inhibitory dose of clotrimazole (CLT) followed by RB-PDT, this order was critical, significantly
reduced the exposure times required to achieve 100% inhibition of T. rubrum to 15 minutes as compared to RB-PDT
alone.
Conclusions: The combination of antifungal drug and RB-PDT represents an attractive alternative to the current
antifungal therapies used to treat superficial fungal diseases. Our approach has the potential to reduce treatment
times and drug dosages which can also reduce drug toxicity and improve patient compliance.
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Dermatophytic fungi cause a range of superficial diseases,
termed dermatophytoses, which affect keratinised tissues
of humans such as the skin, hair and nails [1]. Fungal
infections of the skin and nails are easily spread and
have a worldwide distribution. However, the incidence
and severity tends to be greater in those with compromised
immune systems [2]. Individuals such as the young and old
or those suffering from underlying conditions such as
HIV, diabetes mellitus and cancer patients undergoing
chemotherapy are at greatest risk [2,3]. Furthermore,
fungal infections can be very challenging to treat with
high recurrence rates [4].
Treatment of fungal infections involves either the ad-
ministration of topical or oral antifungal agents (systemic)
or a combination of both depending on the area infected
(e.g. skin or nails) [5,6]. For treatment of superficial
infections, topical medications containing the antifungal
agent clotrimazole are the most commonly used [7,8].
While more difficult to treat infections such as those
affecting the toenails (termed onychomycosis) are treated
using systemic antifungals agents such as terbinafine [9].
Both fungi and their human hosts are eukaryotes
which limits the number of drugs that display selective
toxicity [10]. Some antifungals with overlapping toxicity
must be used at low doses, which causes some fungal
infections to require extended treatment times of up to
12 months [11]. Patient non-compliance is a major issue
leading to abandonment of treatment, which in turn
contributes to high rates of recurrence. Abandonment can
also be due to the high costs associated with ongoing
treatment [12]. Furthermore, the long-term use of antifun-
gals is contra-indicated in some patients, particularly the
elderly, who may experience drug-drug interactions with
other medications, and in patients with abnormal liver
function [13].
We believe that the ideal antifungal therapy should be
fungicidal in its mode action (actually kills the fungus),
of short duration, easy to take/deliver, have minimal adverse
side-effects, and importantly be affordable. Photodynamic
therapy (PDT) offers an attractive alternative to the use of
antifungal drugs, negating many of the aforementioned
treatment issues. PDT is a non-invasive clinical therapy
currently being utilised in the treatment of skin tumours
[14]. PDT involves the use of visible light (usually a laser),
a non-toxic photosensitiser (PS) or light activated dye and
the presence of molecular oxygen [15,16]. Individually,
these various components are harmless. However, once
activated by the light source the PS becomes energised
to an excited state reacting with molecular oxygen to
generate reactive oxygen species (ROS). The presence of
these toxic ROS leads to the oxidation of biomolecules
that ultimately kill target cells [17-19]. We have previously
demonstrated the antifungal effects of Rose Bengal(RB)-PDT on the fungus Trichophyton rubrum (the
most common cause of superficial mycoses) [20]. While
this research provided proof of concept for the develop-
ment of a novel treatment against T. rubrum it involved
the use of an expensive, high-powered laser making it an
unaffordable option to those most at risk. In an effort to
produce a low cost alternative we then evaluated the
potential of light-emitting diodes (LEDs) within the UVA,
UVB and UVC spectra. Our results demonstrated that ex-
posure at 280 nM (UVC) to T. rubrum spores at a fluence
of 0.5 J/cm2 was germicidal [21]. Unfortunately there are
obvious carcinogenic risks associated with utilising UVC
radiation [22] and as a result we suggested that a more
appropriate use of UVC could be in the decontamination
of patient shoes, which represent potential reservoirs of
re-infection.
The need for a safe, effective and low cost alternative
therapy has led to this current study in which the in vitro
antifungal effects of RB-PDT using an inexpensive green
(530 nm) LED, as a versatile light source, were demon-
strated. We tested our PDT regime as both a stand-alone
therapy and as a component of combinational therapy
with a number of clinically important antifungal drugs
(clotrimazole and terbinafine) [11]. The findings of this
study have the potential to dramatically reduce conven-
tional treatment times, increasing both affordability and
patient compliance.
Results and discussion
We previously demonstrated the antifungal effects of
PDT using 140 μM RB activated using a high-powered
green laser using a fluence of 228 J/cm2 on T. rubrum
spore suspensions [20]. T. rubrum is a clinically signifi-
cant pathogen causing up to 69.5% of all human derm-
atophytosis [23]. In an effort to develop an alternative,
low cost treatment without the need for expensive lasers
our present study investigates the potential of integrat-
ing LEDs as part of a standalone RB-PDT regime and as
a combinational therapy with currently used antifungal
drugs.
Photodynamic activation of RB using a green LED has a
fungicidial effect on T. rubrum spores
There are many benefits to using LEDs including their
versatility in clinical settings, long lifetimes, safety and
low cost. In fact, the light source described in this study
has been made from readily available items found at a
typical electronics store at a cost of approximately US
$50 (Figure 1). Using our RB-PDT regime, T. rubrum
spore suspensions containing RB were irradiated, using a
green LED, for various time periods up to 30 minutes.
Following irradiation, spore suspensions were spread
onto PDA plates and quantified after incubation to assess
fungal viability. Exposure of T. rubrum spores at a fluence
Figure 1 The 530 nm LED lamp system developed for PDT in this study. (A) Internal schematic view of the green LED lamp designed and
constructed by the author for RB-PDT irradiation of T. rubrum spores. (B) LED lamp under operation (bottom left). (C) Circuit diagram of electrical
components comprising the LED lamp (bottom right).
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resulted in the death of 100% of the fungus (Figure 2).
Plates were incubated for a further 8 weeks (post-PDT),
during which time they were monitored weekly. Following
this incubation period no growth was observed on any ofFigure 2 Fungicidal activity of photodynamic treatment using
LED lights at 530 nm and either Rose Bengal or Rose Bengal
diacetate on resting spores of T. rubrum. Data are mean values
and standard error from three replicate experiments; analysed by
two-way ANOVA (* p <0.05, ** p <0.01, ***p <0.001).the plates containing irradiated spores, indicating that the
mechanism of RB-PDT was not simply fungistatic but
fungicidal. In all experiments, irradiation of spores using
the LED light only (i.e. without RB) or non-irradiated RB
(referred to as dark toxicity) did not reduce T. rubrum via-
bility compared with the growth control (See Additional
file 1: Tables S1 & S2). The performance of our LED lamp
system was vastly superior compared to our previous
study using a 532 nm laser. The laser required a much
larger fluence of 228 J/cm2 and resulted in 85% growth
inhibition [14].
Uptake and intracellular localization of RB is not a critical
factor to PDT inhibition of T. rubrum
RB is very soluble in aqueous media and due to its polar
nature accumulates very inefficiently within cells, localiz-
ing to the outside of fungal spores and hyphae [24,25]
(Figure 3). As such its phototoxic effects are restricted
to the cell membrane of T. rubrum spores and other fungi.
In an effort to investigate if it was possible to enhance the
potency of RB-PDT we included RB diacetate (RBAc) in
our study. RBAc is a modified derivative of RB in which
the acetate groups have been added to the xanthene ring
making it more hydrophobic and improving its uptake
Figure 3 Micrographs showing the uptake of Rose Bengal by fungi (A) resting spores and hyphae of T. rubrum, (B) C. albicans and (C) S.
cerevisiae. The images were captured under brightfield and fluorescence microscopy at 400 X magnification; the scale bar (Bottom right) is 10 μm.
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addition of an acetate group is that the photosensitizing
property of the compound is quenched, which is highly
desirable from a clinical viewpoint as it prevents unwantedphotoactivation [24,26]. Following uptake, the acetate
groups are removed by endogenous carboxylic esterases,
restoring the compound’s functional/photosensitizing
capabilities [24].
Figure 4 Fungicidal activity of photodynamic treatment using
LED lights at 530 nm and Rose Bengal on the pathogenic fungi
T. rubrum, C. albicans and S. cerevisiae. Data are mean values and
standard error from three replicate experiments; analysed by
two-way ANOVA (* p <0.05, ** p <0.01, ***p <0.001).
Morton et al. BMC Microbiology 2014, 14:261 Page 5 of 9
http://www.biomedcentral.com/1471-2180/14/261The spore stage of T. rubrum was targeted because the
spores are thought to be the primary means by which
humans become infected and re-infected [27] and can be
used to make standardised inoculum. Spores are the
dormant stage of the fungus and have been demon-
strated to be more resistant than hyphae to the uptake
and inhibitory effects of antifungal agents [28]. How-
ever, despite their importance in disease transmission,
very little is known regarding the enzymatic activities of
dormant T. rubrum spores. When we employed RBAc
as the photosensitizer in our PDT regime, there was
significantly less fungal growth inhibition (68% ±12)
compared to that achieved by RB-PDT (99.7% ±0.1)
(Figure 2). This result suggested that there were low
levels of carboxylic esterase activity associated with T.
rubrum spores and as a result the remaining studies
were carried out using RB.
RB-PDT displays broad-spectrum antifungal inhibition and
is effective against dermatophytic fungi and yeasts
RB has previously been demonstrated to kill a number
of pathogenic microoganisms including protozoa [29],
Gram-positive bacteria [30] and T. rubrum [20]. In the
current study the effect of our PDT regime was also
tested on the pathogenic yeast Candida albicans and the
model fungus Saccharomyces cerevisiae. The most com-
mon cause of fungal disease is C. albicans, which causes a
range of conditions from superficial infection of mucous
membranes to potentially fatal invasive infections and
septicaemia [31]. An emerging issue with infections
caused by Candida spp. is drug resistance with an
increasing frequency of azole resistance occurring in
clinical isolates [32]. This has driven the need for the
development of additional and novel antifungals to
combat this pathogenic fungus. A further complication
with Candida spp. is their ability to form biofilms not
only when causing infection but on medical devices [18].
S. cerevisiae and C. albicans were both sensitive to our
RB-PDT regime further highlighting the broad-spectrum
capabilities of RB-PDT against fungi (Figure 4). Both S.
cerevisiae and C. albicans were significantly more sensi-
tive to RB-PDT than T. rubrum spores (Figure 4). This
indicates that RB-PDT could be a potent therapeutic
option for a number of pathogenic fungi. Furthermore, a
recent study has also demonstrated the broad-spectrum
inhibitory effectiveness of RB-PDT at reducing the growth
of the pathogenic fungi Fusarium solani, Aspergillus fumi-
gatus and C. ablicans [33]. Studies utilising different PDT
protocols and different photosensitisers, e.g. methylene
blue and photogem, have also reported promising results
against C. albicans that indicate that PDT can act much
more quickly than antifungal drugs [18,34]. However,
some studies have reported varied success with Candida
spp., noting that biofilms exhibited greater resistance toPDT [18]. The obvious potential of PDT has led to the
early development of patch delivery systems for the
treatment of oral Candidiasis. Experiments in murine
models used adhesive patches to apply the PS photogem
to the oral cavity; this was followed by exposure to a red
LED light resulting in significant reductions in C. albicans
viability [35].
RB-PDT is potentially effective as a combination therapeutic
The use of combination drug strategies is well established
in mycology, particularly in treating infections caused by
Candida spp. [28]. However, there is very little informa-
tion available on whether antifungal PDT could be ulitised
as an adjunct therapy with antifungal drugs. Prior to com-
bining antifungal therapy with RB-PDT we first needed
to establish the MIC of our clinical isolate to three
commonly used antifungal agents, clotrimazole (CLT),
miconazole (MCZ) and terbinafine (TRB). Both CLT
and MCZ are over-the-counter (OTC) topical antifun-
gal azoles, while TRB, an allylamine, is the mainstay of
orally administered treatments for onychomycosis
[4,9]. Using a modified microdilution method, based
on the Sensititre YeastOne™ assay (Thermo Fisher,
Australia), the MICs for CLT, MCZ and TRB for T.
rubrum were 0.5 μg/mL, 0.2 μg/mL and 0.01 μg/mL
respectively. Our combination therapy protocol involved
pre-incubation of spores at sub-inhibitory concentrations
of either CLT (0.1 μg/mL), or MCZ (0.1 μg/mL), or TRB
(0.005 μg/mL) at 30°C for 72 hours prior to undergoing
our RB-PDT regime. These sub-inhibitory concentra-
tions were five and two times lower than the MICs of
each of the respective drugs alone.
The results of our combined antifungal drug/RB-PDT
regime are shown in Figure 5. Exposure of spores to
pre-treatment with CLT followed by RB-PDT resulted in
Figure 5 Fungicidal activity of drug treatment combined with
photodynamic treatment using LED lights at 530 nm and Rose
Bengal on T. rubrum. Data are mean values and standard error
from three replicate experiments; analysed by two-way ANOVA
(* p <0.05, ** p <0.01, ***p <0.001).
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24 J/cm2 to 12 J/cm2 compared to non-drug treated
controls (i.e. lowering the time to achieve 100% kill from
30 minutes to 15 minutes). A significant though, less
pronounced, inhibitory effect was demonstrated when
a sub-inhibitory concentration of TRB was used. In
contrast, a combination of sub-lethal MCZ (0.1 μg/mL)
followed by RB-PDT did not show enhanced inhibition,
producing a similar dose–response curve to the non-
drug-treated controls, which were also subjected to
RB-PDT. This was surprising considering the findings
of a number of groups demonstrated that the antifun-
gal MCZ actually induced ROS production in both
Candida and S. cerevisae [36,37]. In fact, Snell et al.,
suggested that MCZ could be used to increase the efficacy
of PDT. We did not see a similar increase in efficacy/sen-
sitivity under our PDT regime although it should be noted
we used a much lower concentration of MCZ, 0.1 μg/mL
as compared to 25 μg/mL [37].
Interestingly, a modest increase in the dark toxicity of
RB (i.e. in the absence of light activation) was noted when
T. rubrum spores were pre-incubated at sub-inhibitory
concentrations of the aforementioned drugs and allowed
to germinate followed by incubation in 140 μM RB (i.e.
not photoactivated) (See Additional file 1: Table S3). This
increase in dark toxicity suggests that even at sub-lethal
doses, these drugs were capable of weakening/destabilising
the cell membrane of germinated spores/hyphae enabling
an increased uptake/penetration of RB. It is important to
note that neither 140 μM RB nor sub-lethal concentra-
tions of CLT, MCZ and TRB individually, under the same
experimental conditions, had an inhibitory effect on the
viability of T. rubrum. Thus the presence of sub-lethal
drug doses of CLT or TRB resulted in enhanced sensitivityto RB-PDT compared to non-drug treated controls. A
similar finding was also observed after pretreatment of C.
ablicans with saponin, a compound capable of creating
pores in fungal membranes that significantly increased the
uptake and photodynamic effects of RB [38]. Other
pretreatment and PDT regimes have utilised specific
inhibitors of cellular functions such as antimycin A which
was shown to synergistically increase the efficacy of PDT
against Candida spp. [39].
It has been demonstrated that PDT using methylene blue
caused increased membrane permeability in C. albicans
making it more susceptible to drug treatment [40]. The
same authors suggested that this could be a useful strategy
in overcoming problems with drug resistance issues in
C. albicans. However, when we changed the order of
our combination protocol, first subjecting T. rubrum
spores to sub-inhibitory doses of RB-PDT (fluence of
12 J/cm2) followed by drug treatment with CLT, MCZ,
TRB and using standardised YO10 YeastOne Sensititre
plates (Thermo Fisher, Australia), we noted no reduction
in the MICs for any of the nine antifungal drugs tested
(See Additional file 1: Table S4).
Future potential and clinical relevance
While these results are based on in vitro spore suspensions
and thus their clinical relevance has yet to be evaluated,
they are very encouraging and merit further investigation.
Our results using sub-inhibitory doses of drug are signifi-
cant when one considers that the recommended treat-
ment dose of CLT (Canesten® Bayer) is 10 mg/mL/daily
for up to four weeks to treat superficial and mucosal
infections. The recommend oral dose of TRB (Lamisil®,
Novartis) is 250 mg/day for 2 weeks when treating
tinea pedis and continuous dosing (250 mg/day) for a
minimum of 12 weeks when treating for toenail ony-
chomycosis [9,36]. Interestingly, combination therapy
using PDT and a suboptimal antibiotic treatment in a
mouse wound model, infected with a virulent strain of
the bacterium Pseudomonas aeruginosa, demonstrated a
synergistic therapeutic effect that was capable of curing
60% of mice of this fatal infection [41].
The use of RB in humans has recently received a lot of
attention due to its remarkable potential in cancer therapy
[42,43]. However in contrast to our antifungal PDT ther-
apy, RB isn’t used in combination with PDT, it is directly
injected into the lesion as a 10% solution (PV-10) in a
procedure known as intralesional (IL) PV-10 therapy.
RB appears to be selectively cytotoxic to tumour cells
while sparing any neighbouring healthy cells. Addition-
ally, PV-10 was found to enhance the host’s systemic
immunity to fight the tumours [42]. A topical form of
PV-10, termed PH-10 (0.002-0.01% Rose Bengal), has
successfully completed phase 2 clinical trials for psoriasis
and atopic dermatitis with encouraging results on human
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for use in humans allowing for greater development of
PDT as a treatment for dermatophytoses.
Conclusions
We believe the RB-PDT approach described in this study
holds considerable potential, directed either as a standa-
lone therapy (particularly where the use of antifungals is
contra-indicated) or implemented as an adjunct to con-
ventional antifungal therapy to treat dermatophytoses
caused by T. rubrum and possibly other fungal species.
The use of both green light and RB in treating skin in-
fections is preferential, due to their minimal penetration,
restricting phototoxicity to the site of infection [44].
Furthermore, the enhanced antifungal effects of RB-PDT
when combined with antifungal agents such as clotrima-
zole and terbinafine as shown in this study may allow for




Clinical isolates of T. rubrum 09-043-3609 and Candida
albicans 01-132-1299 were provided by Westmead
Hospital (medical mycology collection, Westmead Hospital,
NSW, Australia), these were maintained on potato dextrose
agar (PDA). Saccharomyces cerevisiae strain BY4743 was
obtained from Thermo Fisher. The T. rubrum isolate was
incubated for fourteen days at 30°C. Following incubation
spores were collected by brushing the mould surface with
5 mL 0.05% Tween 80 solution using a sterile glass rod.
The resultant spore suspension was filtered using a 40 μM
filter (BD, Franklin Lakes, NJ, USA) to remove hyphal
fragments. A haemocytometer was used to adjust the
suspension density to ~3 × 106 cfu/mL using sterile phos-
phate buffered saline (PBS) (Oxoid, Thebarton, Australia).
Construction of light source
The light source was designed and constructed from
basic electronic components to create an effective light
source emitting narrow-bandwidth green light. To enable
the simultaneous irradiation of replicates, light output was
provided by using three 3-watt H-HP803PG LED modules
(Roithner LaserTechnik, Austria). Each module consisted
of a single emitter (producing green light at a dominant
wavelength of 530 nm) pre-mounted on a non-conductive
20 mm hexagonal base. LED modules were wired in series
to a 2.2Ω, 5 watt wire-wound resistor. The entire
assembly was enclosed in a rigid ABS plastic casing
(sealed, except for circular holes for fan ventilation and
light projection) to enable practical use and protect the
components from physical handling. To provide fur-
ther cooling and thermal stability for the LEDs, a 12 V,
8000 rpm, 30 mm cooling fan was connected in parallel tothe LED series circuit, and for passive cooling, a 6°C/W,
aluminium pin-type heatsink was attached to the base
of each LED module using double-sided thermal tape
(Figure 1). The directional output of each LED was fo-
cused into a narrow beam by attaching a 10° lens collima-
tor (internal to the casing) and 30 mm-length polymer
tubing (external to the casing) to the emitting side of each
module using epoxy putty and cyanoacrylate adhesive
(Selleys, Australia). This arrangement changed the light
beam pattern to a circular spot size of 0.785 cm2 and
confined the light output of each LED to a single well of a
black 96-well microplate (Greiner Bio-One, Frickenhausen,
Germany), eliminating cross-interference with other wells
(Figure 1). The irradiance of each LED was measured at
13.4 mW/cm2 using a laser power meter (GentecEO,
Canada). Heat transfer from the green LED lamp to the
sample and surrounding environment was measured,
using a K-type thermocouple connected to a digital multi-
meter (YH-103, YH, China), to ensure that any resulting
inhibitory effect evident following RB-PDT was not the
result of photothermal effects produced as a result of the
lamp system itself (See Additional file 1: Table S5).
Photodynamic treatment
A stock solution of Rose Bengal (RB) (Sigma Aldrich,
Castle Hill, Australia) was prepared at a concentration of
280 μM in PBS (pH 7.4). The solution was filter sterilized
using a 0.22 μm filter (Millipore, Billerica, MA, USA) and
wrapped in aluminium foil to prevent unwanted photoac-
tivation. Sample preparation consisted of the addition of
50 μL of 280 μM rose bengal and 50 μL of spore suspen-
sion (3 × 106 cfu/mL), specifically microconidia, to wells
of a black 96-well microplate. The plate was covered in
aluminium foil and incubated with shaking at 150 rpm for
30 minutes at 30°C. Samples were irradiated separately
using the LED lamp system for 0, 5, 10, 15 and 30 minutes
respectively under aseptic conditions in a laminar flow
hood. In the untreated control (RB-L-) and photothermal
(RB-L+) treatments, RB was replaced by PBS in both
circumstances and irradiated as above.
Fungal viability following RB-PDT was determined by
diluting the samples 1:10 with PBS and 50 μL aliquots of
the diluted sample was spread onto PDA plates (three
plates per sample) then incubated at 30°C for 96 hours.
After incubation, colonies were enumerated and the
viability was expressed as the ratio of the treated cells
relative to untreated cells. Independent experiments
were performed at least three times and the results
subjected to statistical analysis.
Susceptibility of T. rubrum to clotrimazole, miconazole
and terbinafine
The MICs of the antifungal drugs clotrimazole, micona-
zole and terbinafine (Sigma-Adrich, Castle-Hill, Australia)
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ating alamarBlue® (Life Technologies, Mulgrave, Australia)
as a viability indicator. This method was similar to the
standardised YO10 YeastOne Sensititre Plate System
(Thermo Fisher, Australia). Stock solutions of micona-
zole and terbinafine-HCl were prepared in a glass vial
by dissolving the drug in DMSO (dimethyl sulfoxide) to
attain a final drug concentration of 10 mg/mL. Clotrima-
zole was prepared to a stock concentration of 5 mg/mL
using an identical method. All stock solutions were stored
at −20°C.
Samples were prepared by sequentially adding 200 μL
of 10x alamarBlue® stock solution, 20 μL of T. rubrum
spore suspension (3 × 106 cfu/mL), 780 μL YeastOne broth
(Thermo Fisher, Australia) and mixed evenly. 50 μL of this
mixture was pipetted into each well of a 96-well plate
containing the required drug ranges. Drugs were pre-
pared by serial dilution to achieve drug concentrations
of 0.01 μg/mL and 0.5 μg/mL for clotrimazole and mi-
conazole, and 0.001 to 0.005 μg/mL for terbinafine. The
96-well plate was sealed with a lid and polyethylene film
to prevent evaporation; the plate was incubated at 30°C
for 96 hours with shaking. Colour changes (purple or
pink) were read visually. The MICs of both drugs were
determined to be the lowest drug concentration in
which no growth occurred. Independent experiments
were performed at least three times and the results sub-
jected to statistical analysis.
Combination therapy
Our combination therapy consisted of exposure to a
sublethal dose of antifungal agent followed by RB-PDT.
Assays were performed by combining 500 μL of a T.
rubrum spore suspension (3 × 106 cfu/mL) with 400 μL
YeastOne broth (Thermo Fisher, Australia) followed by
the addition of either clotrimazole (final concentration
0.1 μg/mL), miconazole (final concentration 0.1 μg/ml)
or terbinafine-HCl (final concentration 0.005 μg/mL) to
a final volume of 1.0 mL. Samples were incubated for
72 hours at 30°C. Independent experiments were per-
formed at least three times and the results subjected to
statistical analysis. Following the incubation period,
drug-treated spore suspensions, consisting of germi-
nated spores/hyphae following the 72 hours growth
period, were subjected to RB-PDT (described earlier).
Post-PDT samples were diluted 1:5 and 50 μL aliquots
per sample were plated onto three PDA plates. The
plates were incubated at 30°C for 96 hours and the per-
centage survival determined for each drug-PDT treat-
ment by enumerating the cfu/mL.
Statistical analysis
Quantitative data for the effects of PDT were compared
by two-way ANOVA between relevant treatments usingGraphpad Prism Version 5.02 for Windows (Graphpad
Software, San Diego, CA, USA).
Additional file
Additional file 1: Table S1. Dark Toxicity of 140 μM of Rose Bengal
tested against different fungi. Table S2. Effect of exposure to light from
the LED system on fungal viability. Table S3. Dark toxicity of 140 μM
Rose Bengal following a 72 hr/30°C incubation of T. rubrum spores in
sub-inhibitory concentrations of a number of antifungal drugs: clotrimazole
(CTL: 0.1 μg/ml); miconazole (MCZ: 0.1 μg/ml); and terbinafine hydrochloride
(TRB: 0.005 μg/ml) (n = 3). Table S4. Changes in drug MIC against Trichophyton
rubrum following RB-PDT (140 μM Rose Bengal and 12 J/cm2). Table S5.
Measurement of heating effects due to the LED system during activation.
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